Historic Cannabis Seed Giveaway is a Huge Hit at 2025 California State Fair
SAN FRANCISCO, July 15, 2025 /CNW/ -- Humboldt Seed Company (HSC), California's largest licensed cannabis seed provider, is making history at the State Fair with a 15,000-seed giveaway, part of its mission to empower home growers. The giveaway continues through July 27 at Cal Expo in Sacramento.
Fairgoers can visit the Embarc counter at the California Cannabis Experience and receive 3 cannabis seeds for one cent, keeping in compliance with all state regulations. The seeds are sourced from HSC's annual phenohunting project—an advanced selection process aimed at identifying the best cannabis strains for its ongoing breeding program.
"This is more than just a giveaway—it's an opportunity to spotlight cannabis as a premium California agricultural product and inspire consumers to discover the benefits of growing their own," said Benjamin Lind, Co-founder and Chief Science Officer of Humboldt Seed Company. "The enthusiasm we're seeing has exceeded our expectations."
This significant industry milestone is the largest legal cannabis seed distribution ever undertaken at a public event. It represents an important moment for the destigmatization of cannabis and brings home growing into the mainstream gardening realm.
"We're thrilled to partner with Humboldt Seed Company. Their commitment to scientific innovation, genetic excellence, and environmental stewardship aligns perfectly with our mission," said Dustin Moore, Co-founder and Chief Strategy Officer of Embarc. "And we're just getting started. In the coming weeks, we'll announce a new collaboration that combines world-class genetics with responsible retail practices to create memorable experiences for concertgoers. We're moving cannabis from the parking lot to the main stage."
About Humboldt Seed Company
Established in 2001, Humboldt Seed Company is a Northern California heritage brand providing quality cannabis genetics to commercial cultivators and home growers in legalized states across the U.S. and international markets, including Europe, Jamaica, St. Vincent, Antigua, Uruguay, Brazil, Argentina, Canada, and the U.K. With a focus on environmental and social justice, HSC combines traditional breeding and modern scientific practices in its strain development program.
For more information visit https://humboldtseedcompany.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Highlights: Strong Sales Growth Amid Challenges
Worldwide Sales: $23.7 billion, a 4.6% increase. Innovative Medicine Sales: $15.2 billion, a 3.8% increase. MedTech Sales: $8.5 billion, a 6.1% increase. Net Earnings: $5.5 billion. Diluted Earnings Per Share (EPS): $2.29, up from $1.93 a year ago. Adjusted Net Earnings: $6.7 billion. Adjusted Diluted EPS: $2.77, a 1.8% decrease from the previous year. Operational Sales Growth: 4.6% overall, 3.8% in Innovative Medicine, 6.1% in MedTech. Oncology Sales Growth: 22.3% operational growth. Cardiovascular Sales Growth: Over 22% operational growth. Free Cash Flow: Exceeded $6 billion in the first half of 2025. Cash and Marketable Securities: $19 billion. Debt: $51 billion, resulting in a net debt position of $32 billion. Effective Tax Rate: 14.7% for the quarter. Full-Year Sales Guidance Increase: Raised by $2 billion. Full-Year EPS Guidance Increase: Raised by $0.25 to a range of $10.80 to $10.90. Warning! GuruFocus has detected 8 Warning Signs with CGEAF. Release Date: July 16, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Johnson & Johnson (NYSE:JNJ) reported a strong operational sales growth of 4.6% across its business in the second quarter of 2025. The company achieved over $15 billion in quarterly sales for the first time in its Innovative Medicine segment, despite the loss of exclusivity for STELARA. MedTech division delivered 6.1% operational sales growth, with significant momentum in cardiovascular surgery. Johnson & Johnson (NYSE:JNJ) raised its full-year sales guidance by $2 billion and EPS guidance by $0.25. The company is making significant progress in oncology, with a 22.3% operational sales growth and a bold vision to become the number one oncology company by 2030. Negative Points The loss of exclusivity for STELARA posed a significant headwind, impacting sales by approximately 710 basis points. Adjusted net earnings for the quarter decreased by 2.1% compared to the second quarter of 2024. The orthopedics business declined by 1.6%, driven by competitive pressures and transformation programs. MedTech margin declined from 25.7% to 22.2% due to macroeconomic factors and cost of products sold. Interest income and expense shifted to a net expense of $48 million from $125 million of income in the second quarter of 2024, primarily due to lower interest rates and higher debt from acquisitions. Q & A Highlights Q: J&J reported strong top-line growth despite the STELARA loss of exclusivity. What are the main drivers of this growth, and how do the Innovative Medicine and MedTech segments contribute? A: Joseph Wolk, CFO, highlighted that both segments contributed significantly to the strong performance. Jennifer Taubert, EVP of Innovative Medicine, noted that the business achieved its first $15 billion quarter, with 13 brands growing double digits. Tim Schmid, EVP of MedTech, mentioned cardiovascular growth of 22% and strong performance in vision and surgery as key contributors. Q: Can you elaborate on the oncology target of $50 billion by the end of the decade? What are the key growth areas? A: Jennifer Taubert, EVP of Innovative Medicine, expressed confidence in the $50 billion target, citing strong growth in multiple myeloma with DARZALEX and CARVYKTI, and the potential of TAR-200 in bladder cancer. John Reed, EVP of R&D, added that the oncology pipeline has strong momentum, with promising developments in colorectal and head and neck cancers. Q: The guidance implies an acceleration in top-line growth in the second half of the year. Can you comment on the potential for growth in 2026 and beyond? A: Joseph Wolk, CFO, indicated that 2026 is expected to see better growth than 2025, driven by new product introductions and in-line brands receiving new indications. He also mentioned that margin improvement will be assessed as the year progresses. Q: How is J&J preparing for the potential impact of pharma tariffs, and what is the flexibility of your manufacturing supply chain in the US? A: Joaquin Duato, CEO, stated that J&J is committed to manufacturing in the US and has a plan to invest $55 billion over the next four years to ensure that all medicines consumed in the US are manufactured domestically. Q: Can you provide an update on the OTTAVA Robotic Surgical System and the electrophysiology (EP) strategy? A: Tim Schmid, EVP of MedTech, confirmed that OTTAVA is on track with its milestones, with a de novo submission expected in the first quarter of next year. He also highlighted the strong performance in EP, driven by the adoption of VARIPULSE and the strategic differentiation of the Cardio systems. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
WithSecure Corp (FRA:DTV0) Q2 2025 Earnings Call Highlights: Strategic Shifts and Growth ...
Elements Cloud and Co-Security Services Growth: 13% increase driven by new products and mid-market playbook. Managed Services Decline: 22% decrease due to enterprise customers shifting to in-house solutions. Annual Recurring Revenue (ARR) Growth: 3% overall growth. Cloud Protection for Salesforce Growth: 54% year-over-year growth, despite a slower quarter. Net Revenue Retention (NRR) for Cloud Protection for Salesforce: 122%, slightly down from the previous quarter. Combined Net Revenue Retention: 99%, impacted by managed services decline. Revenue Increase: 3% increase in the quarter. Operating Expenses (OpEx): Continued reduction as part of efficiency measures. Restructuring Impact: Expected annual cost reduction of EUR 6.5 million. Outlook for Elements ARR Growth: Expected to grow 10% to 20% for the year. Outlook for Cloud Protection for Salesforce Growth: Expected to grow 20% to 35% for the year. EBITDA Margin Outlook for Elements Company: Expected to be between 3% and 7% of revenue. Warning! GuruFocus has detected 5 Warning Signs with FRA:DTV0. Release Date: July 16, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points WithSecure Corp (FRA:DTV0) launched new extensions to their Elements Cloud and co-security services, enhancing exposure management and detection capabilities. The company achieved a 13% growth in Elements Cloud and co-security services, driven by new products and partnerships. WithSecure Corp (FRA:DTV0) successfully divested its Malaysian entity, establishing LS Systems as a preferred distributor in the region. The company reported a positive adjusted EBITDA, marking a significant improvement from the previous year. WithSecure Corp (FRA:DTV0) is seeing increased demand for European cybersecurity solutions, particularly in the public sector, due to discussions around digital sovereignty. Negative Points The company experienced a 22% decline in managed services revenue due to churn from large enterprise customers. WithSecure Corp (FRA:DTV0) reported only a 3% growth in annual recurring revenue (ARR), impacted by managed services decline. Foreign exchange effects negatively impacted the ARR for Cloud Protection for Salesforce by approximately 400k. The company faces challenges in transitioning from large enterprise customers to a mid-market focus, impacting revenue. Despite groundwork and partnerships, the positive impacts are not yet fully reflected in the financial numbers. Q & A Highlights Q: Was the decline in managed services during Q2 in line with your expectations, and should we expect this trend to continue in the second half of the year? A: Tom Jansson, CFO: We were aware of potential risks with large enterprise customers, and this was factored into our guidance. We are maintaining our guidance for the rest of the year. Antti Koskela, CEO: Our growth model focuses on the mid-market and partners, which we believe will drive momentum. Q: Can you describe the pipeline for the Elements Cloud business and what gives you confidence in meeting your guidance? A: Antti Koskela, CEO: There's a growing understanding that modern cybersecurity requires more than just endpoint protection. We see existing partners and customers upgrading to other modules. Additionally, partners like those in the Netherlands are selling managed security services, which gives us confidence in our opportunities. Q: Regarding the EUR6.5 million savings target, is this a net savings number, or will some of it be reinvested into the business? A: Antti Koskela, CEO: That is a net saving. We are transitioning from a regional sales structure to a globally aligned one, focusing on mid-market and smaller customers, which will drive efficiencies. Q: How much of the planned cost cuts are due to a structural change in your business model versus a response to lower demand from large customers? A: Antti Koskela, CEO: The cost cuts are 100% aligned with our strategy to focus on partners serving the mid-market. This has been part of our plan, and we are now executing it following recent transactions. Q: Can you provide a ballpark figure for the FX-neutral growth in the Cloud Protection for Salesforce segment this quarter? A: Tom Jansson, CFO: Our ARR was reduced by approximately 400k due to FX effects. Without this impact, the growth would have been higher. Q: Do you expect the digital sovereignty discussions in Europe to lead to increased demand this year? A: Antti Koskela, CEO: We are already seeing increased demand from partners, as evidenced by our partnership with DNA in Finland and activities in the Netherlands. This gives us confidence in the growing interest in European cybersecurity solutions. Q: How much will the cost savings benefit this year's results? A: Tom Jansson, CFO: The EUR6.5 million net savings will start to impact from Q4 onwards, with a large portion expected to materialize depending on the process. Q: What is the outlook for ARR growth in the second half of the year, and what gives you confidence in achieving it? A: Antti Koskela, CEO: We have a strong sales funnel and quality partnerships, which form the basis of our ARR guidance. We need to execute effectively to capture these opportunities. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Barco NV (BCNAF) (H1 2025) Earnings Call Highlights: Strong Growth in Healthcare and ...
Revenue Growth: Orders and sales increased by 5% year over year. Order Book: Increased by 3% year over year, landing at EUR548 million. Gross Profit Margin: 40% of sales, up 0.3 percentage points. EBITDA: EUR48 million, representing 10.6% of sales, up 2.5 percentage points from last year. Free Cash Flow: EUR21.4 million, up EUR6.8 million year over year. Net Income: EUR23 million, doubled compared to last year. Working Capital: 12.2% of sales, with a nominal reduction of EUR50 million year over year. Return on Capital Employed (ROCE): 16%, up 5 percentage points year over year. Net Cash: EUR182 million, EUR10 million higher than a year ago. Healthcare Division: Orders up 15%, sales up 5%, EBITDA at 12.5% of sales. Enterprise Division: Sales down 5%, EBITDA at EUR8.6 million, 8% of sales. Entertainment Division: Sales up 10%, EBITDA at 10.6% of sales. Warning! GuruFocus has detected 8 Warning Signs with FRA:BLRB. Release Date: July 16, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Barco NV (BCNAF) reported a 5% increase in both orders and sales, driven by strong performance in Healthcare and Entertainment sectors in the Americas and EMEA. The company's EBITDA margin improved to 10.6% of sales, up 2.5 percentage points from the previous year, indicating effective cost management and a better product mix. Free cash flow increased to EUR21.4 million, up EUR6.8 million year over year, showcasing improved cash management. Barco NV (BCNAF) has successfully launched new Eco-labeled products, with 70% of revenue now coming from these environmentally friendly offerings. The company maintained a strong net cash position of EUR182 million, providing financial flexibility for future investments or shareholder returns. Negative Points The Enterprise division experienced a 5% decline in sales, with challenges in the Control Rooms segment due to project delays and price competition. APAC region showed softer sales, with a 7% decline, particularly impacted by slow government investments and price competition in China. Tariffs impacted gross profit margins, with an estimated cost of less than EUR5 million in the first half, and potential headwinds expected in the second half. The Modality market faced significant price pressure, especially in China, affecting the overall performance of the Healthcare division. Currency fluctuations, particularly a weakening dollar, are expected to impact EBITDA by EUR7 million to EUR8 million for the full year. Q & A Highlights Q: Could you quantify the impact of tariffs on the gross profit margin, and is there still a headwind expected in the second half of the year? A: The impact on margins was less than EUR5 million in the first semester, primarily in the second quarter. For the remainder of the year, we aim to offset this impact through changes in factories, logistics, and price increases. - Ann Desender, CFO Q: With the recent completion of the share buyback, why not buy back more shares given the strong results and cash position? A: The previous buyback was due to our cash position and perceived undervaluation. While we have the cash, no decision has been made to start a new buyback program. The shares are in treasury and could be used for M&A or canceled, but the decision is up to the Board. - An Steegen, CEO Q: Where do you expect growth in the second half of the year, and where is visibility low? A: We see healthy market conditions in Entertainment, particularly in Cinema and immersive experiences. Healthcare is gaining momentum, especially in Diagnostic Imaging and Surgical. Enterprise faces challenges, but we are expanding our ClickShare offerings. Control rooms are focusing on software development. - An Steegen, CEO Q: Can you elaborate on the sellout of ClickShare and what will drive market growth? A: In the first quarter, sellout was still negative, but we saw slight improvement in the second quarter. The market for wireless conferencing is declining slightly, but we expect stabilization and gradual improvement. - An Steegen, CEO Q: What are your expectations for the new ClickShare hub, and how will it impact margins? A: The ClickShare hub is a new platform co-developed with Microsoft, officially launched in June. It will take time for channels to fully adopt it, with the first releases expected in December. The investment in R&D for this product is significant, impacting margins in the short term. - An Steegen, CEO and Ann Desender, CFO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
